Literature DB >> 15832355

Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers.

Carlo Castellani1, Luigi Picci, Maurizio Scarpa, Maria Cristina Dechecchi, Luisa Zanolla, Baroukh Maurice Assael, Franco Zacchello.   

Abstract

Following cystic fibrosis (CF) neonatal screening implementation, a high frequency of heterozygotes has been reported among neonates with elevated immunoreactive trypsinogen (IRT) and normal sweat chloride levels. We studied the relationship between normal IRT values and CF heterozygosity: 10,000 neonates were screened for CF by IRT measurement and tested for 40 CF mutations; the 294 carriers detected were coupled with newborns negative to the same genetic testing, and the two groups' IRT levels compared. Heterozygotes had higher IRT levels than their controls (mean 35.32 vs. 27.58 microg/L, P<0.001). Even within normal trypsinogen range, the probability of being a CF carrier increases with neonatal IRT concentration. Copyright (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15832355     DOI: 10.1002/ajmg.a.30470

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  11 in total

1.  Newborn screening for cystic fibrosis: techniques and strategies.

Authors:  Bridget Wilcken
Journal:  J Inherit Metab Dis       Date:  2007-05-12       Impact factor: 4.982

2.  Cystic fibrosis newborn screening: distribution of blood immunoreactive trypsinogen concentrations in hypertrypsinemic neonates.

Authors:  Valentina Paracchini; Manuela Seia; Sara Raimondi; Lucy Costantino; Patrizia Capasso; Luigi Porcaro; Carla Colombo; Domenico A Coviello; Tiziana Mariani; Emanuela Manzoni; Monica Sangiovanni; Carlo Corbetta
Journal:  JIMD Rep       Date:  2011-11-04

3.  Factors associated with parental perception of child vulnerability 12 months after abnormal newborn screening results.

Authors:  Audrey Tluczek; Anne Chevalier McKechnie; Roger L Brown
Journal:  Res Nurs Health       Date:  2011-08-24       Impact factor: 2.228

4.  Newborn screening for cystic fibrosis: parents' preferences regarding counseling at the time of infants' sweat test.

Authors:  Audrey Tluczek; Rebecca L Koscik; Peggy Modaff; Darci Pfeil; Michael J Rock; Philip M Farrell; Caroline Lifchez; Mary Ellen Freeman; William Gershan; Christina Zaleski; Bradley Sullivan
Journal:  J Genet Couns       Date:  2006-08       Impact factor: 2.537

Review 5.  Clinical Phenotypes of Cystic Fibrosis Carriers.

Authors:  Philip M Polgreen; Alejandro P Comellas
Journal:  Annu Rev Med       Date:  2022-01-27       Impact factor: 13.739

6.  Newborn screening for cystic fibrosis by use of a multiplex immunoassay.

Authors:  Barbara A Lindau-Shepard; Kenneth A Pass
Journal:  Clin Chem       Date:  2009-12-29       Impact factor: 8.327

Review 7.  Newborn screening for cystic fibrosis: a lesson in public health disparities.

Authors:  Lainie Friedman Ross
Journal:  J Pediatr       Date:  2008-09       Impact factor: 4.406

8.  Improving newborn screening for cystic fibrosis using next-generation sequencing technology: a technical feasibility study.

Authors:  Mei W Baker; Anne E Atkins; Suzanne K Cordovado; Miyono Hendrix; Marie C Earley; Philip M Farrell
Journal:  Genet Med       Date:  2015-02-12       Impact factor: 8.822

9.  Newborn Screening Quality Assurance Program for CFTR Mutation Detection and Gene Sequencing to Identify Cystic Fibrosis.

Authors:  Miyono M Hendrix; Stephanie L Foster; Suzanne K Cordovado
Journal:  J Inborn Errors Metab Screen       Date:  2016-08-01

10.  Screening for cystic fibrosis in New York State: considerations for algorithm improvements.

Authors:  Denise M Kay; Breanne Maloney; Rhonda Hamel; Melissa Pearce; Lenore DeMartino; Rebecca McMahon; Emily McGrath; Lea Krein; Beth Vogel; Carlos A Saavedra-Matiz; Michele Caggana; Norma P Tavakoli
Journal:  Eur J Pediatr       Date:  2015-08-21       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.